secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0001099800-22-000016
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q2 sales flat at $1.37B; lowers FY2022 outlook on FX, staffing
----------------------------------------------------------------------

- Q2 sales $1.37B flat YoY; underlying growth 5%. GAAP EPS $0.65, adjusted EPS $0.63.
- TAVR sales $907M (+1% reported, +5% underlying); TMTT $28M; Surgical $229M; Critical Care $211M.
- Full-year sales guidance lowered to $5.35-$5.55B; adjusted EPS guided to low end of $2.50-$2.65.
- Q2 share repurchases of $355M; Board approved new authorization with $1.9B remaining.
- Adjusted gross margin improved to 80.5% from 75.9%, helped by FX hedge gains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980022000016/0001099800-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980022000016/ew-20220728.htm
  HTML page:      https://secwatch.observer/filing/0001099800-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer